Group 1 - The conference call is focused on the update of Capricor Therapeutics' DMD (Duchenne Muscular Dystrophy) program [1] - The Chief Financial Officer, A.J. Bergmann, emphasizes that forward-looking statements will be made regarding product efficacy, safety, and future R&D plans [2] - The company will discuss various aspects including revenue estimates, manufacturing capabilities, and potential regulatory developments related to their product candidates [3]